Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).

Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).

Item
http://www.wikidata.org/entity/Q33623576
Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina.Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD studySaponins of Panax notoginseng: chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases.Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients.Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus.The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen).Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.Widely Used Types and Clinical Applications of D-Dimer Assay.Panax notoginseng Saponins for Treating Coronary Artery Disease: A Functional and Mechanistic Overview.Regular walking improves plasma protein concentrations that promote blood hyperviscosity in women 65-74 yr with type 2 diabetes.Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
P2860

Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).

Item
http://www.wikidata.org/entity/Q33623576
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@ast
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@en
type
label
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@ast
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@en
prefLabel
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@ast
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Comparison of plasminogen acti ...... ease (from the BARI 2D trial).
@en
P2093
P2860
P304
P31
P356
10.1016/J.AMJCARD.2009.08.643
P407
P433
P478
P50
P577
P5875
P698
P921
P932